Thursday, January 26, 2017

UPDATE 1-Bristol-Myers cuts 2017 outlook amid Opdivo competition

Jan 26 (Reuters) - Bristol-Myers Squibb Co on

Thursday posted fourth-quarter profits that fell short of Wall

Street estimates and lowered its 2017 earnings forecast amid

tempered expectations for its key Opdivo immuno-oncology drug.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)